Type 2 diabetes mellitus and chronic hepatitis C: Which is worse? Results of a long-term retrospective cohort study

Giordanino, Chiara; Ceretto, Simone; Bo, Simona; Smedile, Antonina; Ciancio, Alessia; Bugianesi, Elisabetta; Pellicano, Rinaldo; Fagoonee, Sharmila; Versino, Elisabetta; Costa, Giuseppe; Arese, D.; Sacco, Marco; Rizzetto, M.; Saracco, Giorgio Maria

doi:10.1016/j.dld.2011.12.003

Cited by 14 publications

(12 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increased metabolic risk associated with HCV infection is supported either by cross‐sectional and longitudinal studies: the prevalence of T2DM in chronic hepatitis C (CHC) ranges between 19‐33% and its incidence is increased in patients with CHC after liver transplantation . In turn, T2DM in CHC seems not only to accelerate the progression of liver disease but also to greatly increase the risk of hepatocellular carcinoma (HCC), even in patients without cirrhosis and after the eradication of HCV infection . For this reason, reducing the incidence of T2DM and improving the glycemic control of diabetic patients with CHC are of paramount importance.…”

Section: Introductionmentioning

confidence: 99%

Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct‐acting antiviral agents

Ciancio

Bosio

et al. 2017

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

Many studies showed insulin resistance amelioration in HCV-patients achieving Sustained Virologic Response (SVR) but results on glycemic control in diabetic patients are unclear. This study aimed to assess fasting glucose (FG) and glycated hemoglobin (HbA1c) values before and after therapy with direct-acting antivirals (DAAs) in HCV-patients with type 2 diabetes mellitus (T2DM). Of the 122 consecutively recruited patients with chronic hepatitis C and T2DM, 110 patients were treated with DAAs and 12 remained untreated. Clinical, biochemical, virological, and metabolic features were collected both at baseline and at 12 weeks after the end of therapy (EOT) or after a comparable period of time in untreated patients. A total of 101 patients obtained a SVR (Group 1), while nine were relapsers. Group 2 (21 patients) was composed by the nine relapsers and the 12 untreated patients. A significant reduction of mean FG (134.3 ± 41.32 mg/dL vs 152.4 ± 56.40 mg/dL, P = 0.002) and HbA1c values (46.51 ± 16.15 mmoL/moL vs 52.15 ± 15.43 mmoL/moL, P < 0.001) was found in Group 1 but not in Group 2 (140.6 ± 47.87 mg/dL vs. 145.31 ± 30.18 mg/dL, P = 0.707, and 55.31 ± 20.58 mmoL/moL vs. 53.38 ± 9.49 mmoL/moL, P = 0.780). In Group 1, 20.7% of patients could reduce or suspend their antidiabetic therapy compared to none in Group 2 (P = 0.03), despite the significant weight increase observed in Group 1. SVR induced a significant amelioration of glycemic control in diabetic HCV-patients, despite a significant weight increase; larger prospective studies are needed to verify whether these results are maintained over the long-term.

show abstract

Section: Introductionmentioning

confidence: 99%

Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct‐acting antiviral agents

Ciancio

Bosio

et al. 2017

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Some comorbidities, such as alcohol consumption in presence of viral hepatitis and obesity, have been found to synergistically increase the risks of HCC and death,11,13 and diabetes has been found to be relevant to poor outcomes in CHC patients 14,15. Anti-HBc positivity has been proven to be unrelated to the prognoses of HCV infections,16 and whether smoking is a risk factor for disease progression and poor prognosis remains controversial 17,18.…”

Section: Discussionmentioning

confidence: 99%

Clinical Model for Predicting Hepatocellular Carcinomas in Patients with Post-Sustained Virologic Responses of Chronic Hepatitis C: A Case Control Study

Zeng

Zhang

et al. 2016

Gut and Liver

View full text Add to dashboard Cite

Background/AimsNo clinical model exists to predict the occurrence of hepatocellular carcinoma in sustained virologic response-achieving (HCC after SVR) patients with chronic hepatitis C (CHC).MethodsWe performed a case-control study using a clinical database to research the risk factors for HCC after SVR. A predictive model based on risk factors was established, and the area under the receiver operating characteristic curve (AUC) was calculated.ResultsIn the multivariate model, an initial diagnosis of compensated cirrhosis and post-SVR albumin reductions of 1 g/L were associated with 21.7-fold (95% CI, 4.2 to 112.3; p<0.001) and 1.3-fold (95% CI, 1.1 to 1.7; p=0.004) increases in the risk of HCC after SVR, respectively. A predictive model based on an initial diagnosis of compensated cirrhosis (yes, +1; no, 0) and post-SVR albumin ≤36.0 g/L (yes, +1; not, 0) predicted the occurrence of HCC after SVR with a cutoff value of >0, an AUC of 0.880, a sensitivity of 0.833, a specificity of 0.896, and a negative predictive value of 0.956.ConclusionsAn initial diagnosis of compensated cirrhosis combined with a post-SVR albumin value of ≤36.0 g/L predicts the occurrence of HCC after SVR in patients with CHC.

show abstract

“…[8] It was also reported that HC viremia is associated with diabetes related complications and comorbidity of chronic HCV infection and DM is associated with a higher mortality rate. [9]…”

Section: Discussionmentioning

confidence: 99%

The spectrum of cutaneous infection in diabetic patients with hepatitis C virus infection: A single-center study from Egypt

El‐Khalawany

Mahmoud

2014

Indian J Dermatol

View full text Add to dashboard Cite

Context:Hepatitis-C virus (HCV) infection and diabetes mellitus (DM) have a significant association with skin disorders. Aims: The aim of this study was to assess the impact of HCV infection on the pattern of cutaneous infections among diabetic patients. Methods and Material: A prospective study included diabetic patients who attended Al-Hussein University hospital, Cairo during the period from 2008 to 2010. Patients were examined for skin infections, and investigated for HCV infection.Statistical Analysis Used:SPSS (version 11.5).Results:The study included 163 patients (102 males and 61 females) with a mean age of 46.2 ± 4.83 years. Ninety five patients (58.3%) were HCV+ve (group A) while 68 patients (41.8%) were HCV-ve (group B). Skin infections in group A included fungal (48.4%), viral (26.3%), bacterial (22.1%) and parasitic (3.2%) while in group B, the spectrum included bacterial (41.2%), fungal (39.7%), viral (11.7%) and parasitic (7.4%). Onychomycosis was the commonest infection in group A (25.2%) compared with folliculitis in group B (19.1%). Cutaneous infections in HCV+ patients were more characterized by increased severity, aggressive course, resistance to treatment and rapid relapse.Conclusions:HCV infection has a significant impact in increasing and changing the spectrum of skin infections in diabetic patients. Severe and resistant infections in diabetics could be an important sign of HCV infection.

show abstract

Type 2 diabetes mellitus and chronic hepatitis C: Which is worse? Results of a long-term retrospective cohort study

Cited by 14 publications

References 39 publications

Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct‐acting antiviral agents

Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct‐acting antiviral agents

Clinical Model for Predicting Hepatocellular Carcinomas in Patients with Post-Sustained Virologic Responses of Chronic Hepatitis C: A Case Control Study

The spectrum of cutaneous infection in diabetic patients with hepatitis C virus infection: A single-center study from Egypt

Contact Info

Product

Resources

About